Diffuse Cutaneous Systemic Sclerosis- Pipeline Insight, 2025
Description
DelveInsight’s, “Diffuse Cutaneous Systemic Sclerosis- Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Diffuse Cutaneous Systemic Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diffuse Cutaneous Systemic Sclerosis: Overview
Diffuse cutaneous systemic sclerosis (dcSSc) is a subtype of systemic scleroderma (systemic sclerosis) and is characterized by skin hardening (fibrosis) and problems in many organs of the body. The prevalence is estimated at about 1/25,000 adults. Women are predominantly affected (F/M sex ratio around 4:1). The disease usually manifests at between 40 and 50 years of age. Pediatric onset can occur but is extremely rare. Raynaud's phenomenon is often the first sign of the disease. The other signs usually appear a few months later. Skin hardening first occurs on the fingers and face, but rapidly becomes generalized. Telangiectasias are sometimes present on the thorax, face, lips, tongue, and fingers. Tendon friction rubs are observed. Esophageal dysmotility is common and provokes gastroesophageal reflux and sometimes dysphagia. Gastrointestinal malabsorption and dysmotility may also be present and are associated with weight loss, vomiting, diarrhea or occlusion. Dry mouth and dental involvement can occur. Arthralgias and acroosteolysis are frequent. Muscular involvement can lead to muscular pain and weakness, and cramps. Severe life-threatening renal involvement may occur (about 2% of cases). Pulmonary fibrosis is frequently seen (60% of cases). Pulmonary hypertension may also occur (10-15% of cases). The exact cause of diffuse cutaneous SSc is unknown. The disease originates from an autoimmune reaction which leads to overproduction of collagen. In some cases, the condition is associated with exposure to chemicals (including silica, solvents and hydrocarbons). Diagnosis is based on typical clinical manifestations and on evidence of specific microangiopathy with giant loops on nailfold capillaroscopy. Skin biopsy is usually not needed. Blood tests must be performed, and show typical antitopoisomerase autoantibodies in 30-40% of cases. The extent of the disease should be evaluated by computed tomography (CT), electrocardiogram, echocardiography, radiography of the hands and esophageal and gastric fibroscopy if needed. The prognosis is severe (10-year survival rate of 60-80%) because of the high risk of life-threatening complications: renal crisis, severe digestive involvement, severe lung fibrosis, and, sometimes, severe heart involvement and pulmonary arterial hypertension.
""Diffuse Cutaneous Systemic Sclerosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diffuse Cutaneous Systemic Sclerosis pipeline landscape is provided which includes the disease overview and Diffuse Cutaneous Systemic Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Diffuse Cutaneous Systemic Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse Cutaneous Systemic Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diffuse Cutaneous Systemic Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diffuse Cutaneous Systemic Sclerosis Emerging Drugs
Further product details are provided in the report……..
Diffuse Cutaneous Systemic Sclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Diffuse Cutaneous Systemic Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:
Diffuse Cutaneous Systemic Sclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse Cutaneous Systemic Sclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse Cutaneous Systemic Sclerosis drugs.
Diffuse Cutaneous Systemic Sclerosis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Diffuse Cutaneous Systemic Sclerosis: Overview
Diffuse cutaneous systemic sclerosis (dcSSc) is a subtype of systemic scleroderma (systemic sclerosis) and is characterized by skin hardening (fibrosis) and problems in many organs of the body. The prevalence is estimated at about 1/25,000 adults. Women are predominantly affected (F/M sex ratio around 4:1). The disease usually manifests at between 40 and 50 years of age. Pediatric onset can occur but is extremely rare. Raynaud's phenomenon is often the first sign of the disease. The other signs usually appear a few months later. Skin hardening first occurs on the fingers and face, but rapidly becomes generalized. Telangiectasias are sometimes present on the thorax, face, lips, tongue, and fingers. Tendon friction rubs are observed. Esophageal dysmotility is common and provokes gastroesophageal reflux and sometimes dysphagia. Gastrointestinal malabsorption and dysmotility may also be present and are associated with weight loss, vomiting, diarrhea or occlusion. Dry mouth and dental involvement can occur. Arthralgias and acroosteolysis are frequent. Muscular involvement can lead to muscular pain and weakness, and cramps. Severe life-threatening renal involvement may occur (about 2% of cases). Pulmonary fibrosis is frequently seen (60% of cases). Pulmonary hypertension may also occur (10-15% of cases). The exact cause of diffuse cutaneous SSc is unknown. The disease originates from an autoimmune reaction which leads to overproduction of collagen. In some cases, the condition is associated with exposure to chemicals (including silica, solvents and hydrocarbons). Diagnosis is based on typical clinical manifestations and on evidence of specific microangiopathy with giant loops on nailfold capillaroscopy. Skin biopsy is usually not needed. Blood tests must be performed, and show typical antitopoisomerase autoantibodies in 30-40% of cases. The extent of the disease should be evaluated by computed tomography (CT), electrocardiogram, echocardiography, radiography of the hands and esophageal and gastric fibroscopy if needed. The prognosis is severe (10-year survival rate of 60-80%) because of the high risk of life-threatening complications: renal crisis, severe digestive involvement, severe lung fibrosis, and, sometimes, severe heart involvement and pulmonary arterial hypertension.
""Diffuse Cutaneous Systemic Sclerosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diffuse Cutaneous Systemic Sclerosis pipeline landscape is provided which includes the disease overview and Diffuse Cutaneous Systemic Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Diffuse Cutaneous Systemic Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse Cutaneous Systemic Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diffuse Cutaneous Systemic Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Cutaneous Systemic Sclerosis.
This segment of the Diffuse Cutaneous Systemic Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diffuse Cutaneous Systemic Sclerosis Emerging Drugs
- FCR 001: Talaris Therapeutics
- Belumosudil: Kadmon Pharmaceuticals
Further product details are provided in the report……..
Diffuse Cutaneous Systemic Sclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Diffuse Cutaneous Systemic Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diffuse Cutaneous Systemic Sclerosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Diffuse Cutaneous Systemic Sclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse Cutaneous Systemic Sclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse Cutaneous Systemic Sclerosis drugs.
Diffuse Cutaneous Systemic Sclerosis Report Insights
- Diffuse Cutaneous Systemic Sclerosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diffuse Cutaneous Systemic Sclerosis drugs?
- How many Diffuse Cutaneous Systemic Sclerosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diffuse Cutaneous Systemic Sclerosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diffuse Cutaneous Systemic Sclerosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diffuse Cutaneous Systemic Sclerosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kadmon Pharmaceuticals
- Talaris Therapeutics
- Horizon Therapeutics
- Mitsubishi Tanabe Pharma
- Takeda Oncology
- Seagen
- FCR 001
- Belumosudil
- HZN 825
- Tepezza
- MT-7117
- Brentuximab vedotin
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Diffuse Cutaneous Systemic Sclerosis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Diffuse Cutaneous Systemic Sclerosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Belumosudil: Kadmon Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diffuse Cutaneous Systemic Sclerosis Key Companies
- Diffuse Cutaneous Systemic Sclerosis Key Products
- Diffuse Cutaneous Systemic Sclerosis- Unmet Needs
- Diffuse Cutaneous Systemic Sclerosis- Market Drivers and Barriers
- Diffuse Cutaneous Systemic Sclerosis- Future Perspectives and Conclusion
- Diffuse Cutaneous Systemic Sclerosis Analyst Views
- Diffuse Cutaneous Systemic Sclerosis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
